PMID- 28835403
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20181113
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 89
IP  - 11
DP  - 2017 Sep 12
TI  - Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
PG  - 1117-1126
LID - 10.1212/WNL.0000000000004354 [doi]
AB  - OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with 
      active relapsing-remitting multiple sclerosis and inadequate response to prior 
      therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in 
      Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients 
      received 2 courses (baseline and 12 months later). Patients could enter an 
      extension (NCT00930553), with as-needed alemtuzumab retreatment for relapse or 
      MRI activity. Annualized relapse rate (ARR), 6-month confirmed disability 
      worsening (CDW; >/=1-point Expanded Disability Status Scale [EDSS] score increase 
      [>/=1.5 if baseline EDSS = 0]), 6-month confirmed disability improvement (CDI; 
      >/=1-point EDSS decrease [baseline score >/=2.0]), no evidence of disease activity 
      (NEDA), brain volume loss (BVL), and adverse events (AEs) were assessed. RESULTS: 
      Most alemtuzumab-treated patients (92.9%) who completed CARE-MS II entered the 
      extension; 59.8% received no alemtuzumab retreatment. ARR was low in each 
      extension year (years 3-5: 0.22, 0.23, 0.18). Through 5 years, 75.1% of patients 
      were free of 6-month CDW; 42.9% achieved 6-month CDI. In years 3, 4, and 5, 
      proportions with NEDA were 52.9%, 54.2%, and 58.2%, respectively. Median yearly 
      BVL remained low in the extension (years 1-5: -0.48%, -0.22%, -0.10%, -0.19%, 
      -0.07%). AE exposure-adjusted incidence rates in the extension were lower than in 
      the core study. Thyroid disorders peaked at year 3, declining thereafter. 
      CONCLUSIONS: Alemtuzumab provides durable efficacy through 5 years in patients 
      with an inadequate response to prior therapy in the absence of continuous 
      treatment. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence 
      that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.
CI  - Copyright (c) 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Coles, Alasdair J
AU  - Coles AJ
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA. ajc1020@medschl.cam.ac.uk.
FAU - Cohen, Jeffrey A
AU  - Cohen JA
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Fox, Edward J
AU  - Fox EJ
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Giovannoni, Gavin
AU  - Giovannoni G
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Hartung, Hans-Peter
AU  - Hartung HP
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Havrdova, Eva
AU  - Havrdova E
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Schippling, Sven
AU  - Schippling S
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Selmaj, Krzysztof W
AU  - Selmaj KW
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Traboulsee, Anthony
AU  - Traboulsee A
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Compston, D Alastair S
AU  - Compston DAS
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Margolin, David H
AU  - Margolin DH
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Thangavelu, Karthinathan
AU  - Thangavelu K
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Chirieac, Madalina C
AU  - Chirieac MC
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Jody, Darlene
AU  - Jody D
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Xenopoulos, Panos
AU  - Xenopoulos P
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Hogan, Richard J
AU  - Hogan RJ
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Panzara, Michael A
AU  - Panzara MA
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
FAU - Arnold, Douglas L
AU  - Arnold DL
AD  - From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of 
      Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and the London School of Medicine, UK; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; Department of Neurology 
      and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles 
      University and General Hospital in Prague, Czech Republic; Neuroimmunology and 
      Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital 
      Zurich and University of Zurich, Switzerland; Department of Neurology (K.W.S.), 
      Medical University of Lodz, Poland; The University of British Columbia (A.T.), 
      Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; 
      Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific 
      Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montreal; 
      Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological 
      Institute, McGill University, Quebec, Canada. M.A.P. is currently affiliated with 
      Wave Life Sciences, Cambridge, MA.
CN  - CARE-MS II and CAMMS03409 Investigators
LA  - eng
PT  - Journal Article
DEP - 20170823
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunologic Factors)
RN  - 3A189DH42V (Alemtuzumab)
SB  - IM
CIN - Neurology. 2017 Sep 12;89(11):1098-1100. PMID: 28835406
CIN - Neurology. 2018 Sep 18;91(12):580. PMID: 30224507
CIN - Neurology. 2018 Sep 18;91(12):581-582. PMID: 30224508
MH  - Alemtuzumab
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Atrophy/diagnostic imaging/prevention & control
MH  - Brain/diagnostic imaging/drug effects
MH  - Disability Evaluation
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunologic Factors/adverse effects/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging/*drug therapy
MH  - Organ Size
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC5595276
EDAT- 2017/08/25 06:00
MHDA- 2017/09/16 06:00
PMCR- 2017/09/12
CRDT- 2017/08/25 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
PHST- 2017/09/12 00:00 [pmc-release]
AID - WNL.0000000000004354 [pii]
AID - NEUROLOGY2016762278 [pii]
AID - 10.1212/WNL.0000000000004354 [doi]
PST - ppublish
SO  - Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 
      2017 Aug 23.